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Abstract
This paper presents a mathematically formalized approach which points out the relation
between efficacy and effectiveness of vaccines. The first term denotes the relative degree of
protection in clinical trials or under ideal conditions, while the latter is based on observed
real-life data. We define the efficacy by a similar formula to the effectiveness, but the
probabilities involved in the relative risk are conditional with respect to the exposure to the
virus. If exposure and vaccination status are independent, the two quantities are equal.
Otherwise, the observed value of the effectiveness is a biased one, as it could be seen for
example in the context of COVID-19 vaccination. This phenomenon is explained by the main
result of this paper, which shows a relation between effectiveness and efficacy involving the
degree of discrimination, a factor which quantifies the asymmetric exposure to the virus of
the vaccinated compared to the unvaccinated group.
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Introduction
This formula is used for computing the vaccine effectiveness under “real life” conditions [2], the main reason being that the involved probabilities can be easily estimated
from the observed statistical data. Nevertheless, these
data may be subject to several bias sources. One possibility is the misclasification of the vaccination status
[1]. The statistics of the COVID-19 pandemic show also
a significant bias of another type. For example, the data
made available by the weekly reports of the German RKI
institute indicate a substantial decline in the effectiveness related to symptomatic infections [5, p. 25]. The explanation given is that the vaccine was developed for an
ancient variant of the virus, while now the delta mutation prevails. But we will see that the main cause is the
asymmetric exposure to the virus of the vaccinated and
unvaccinated group. This fact explains also the apparent
paradox illustrated by the UKHSA Vaccine Surveillance
Reports from November 2021 [6, p. 33]. Except for the age
group under 18, where the vaccination rate is the smallest, in all other cohorts the incidence (as positive tests,
not only symptomatic cases) among vaccinated individuals is larger than that among unvaccinated of the same
age group. This is explained in the report by the different
behaviour of the groups of vaccinated and unvaccinated
individuals, for example unvaccinated are more cautious
than vaccinated, which may feel more safe and behave
1 Dortmund University of Applied Sciences and Arts, Germany
“normally,” or by the natural immunity acquired by a

The notions of efficacy and effectiveness related to vaccines have in the literature slightly different meanings,
since researchers were always aware of the fact that the
values computed by a the same formula in clinical trials
and/or under ideal conditions differ in most cases from
the values based on “real-life” data [3]. The normal approach in order to estimate the quality of a vaccine is to
compute the relative risk in the vaccinated group compared to the unvaccinated group. Therefore, the vaccine
effectiveness (or observed effectiveness) V E is defined by
the formula
P (I | V )
VE =1−
,
(1)
P (I | V ′ )
with the obvious notations: I for “infected,” V for “vaccinated,” and V ′ for “unvaccinated.” Applying Bayes’
formula we obtain
P (V ′ )
P (V | I)P (I)
·
(2)
VE =1−
P (V )
P (V ′ | I)P (I)
P (V | I) P (V ′ )
=1−
·
(3)
P (V ′ | I) P (V )
P (V | I)
P (V )
=1−
/
(4)
1 − P (V | I) 1 − P (V )
P (V ) − P (V | I)
=
.
(5)
P (V )(1 − P (V | I))
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part of the former group. Another explanation for reduced infection rates among unvaccinated, perhaps the
most important one, can be given by the restrictions imposed upon them, for example prohibition to attend public gatherings, gastronomy, entertainment, shopping, etc.
This means that being vaccinated doesn’t necessarily
come along with a higher risk of being infected with
SARS-CoV2, since the formulas (4), (5) can be biased
by the possible dependence of vaccination and exposure
to the virus. If the bias is very strong, their values are in
fact meaningless for estimating the quality of a vaccine.
The main result of this paper gives a precise relation
which is able to explain such facts. The organization is
as follows.
In Section 2 we define the notions of efficacy and degree
of discrimination and give a motivation for this choice.
Briefly stated, in our framework, motivated mainly by
the COVID-19 pandemic, where the probabilities of exposure of vaccinated and unvaccinated individuals can be
highly different, a more relevant measure for the quality of a vaccine would be to take all probabilities in the
formulas (1)–(5) as conditional ones with respect to E,
i.e. exposure to the virus, PE (·) or P ( · | E), and define the result as the efficacy denoted by V E ∗ . We will
show that this definition is consistent with the usual one
used in epidemiology. In well designed clinical trials, the
exposure probability should be independent on the vaccination status (otherwise, the crude statistical data would
be not relevant). In this case we will show that under this
assumption of independence, the efficacy estimated from
such trials coincides with our definition using conditional
probabilities.
In the context of clinical trials described above, it is obvious that no discrimination takes place among the groups
of vaccinated and unvaccinated. However, in the real life,
especially in the COVID-19 context, things turn out to
be different. We define therefore a quantity called degree
of discrimination. It is computed by a similar formula to
(1), by replacing I with E and switching V and V ′ . This
number, given by “1 − the relative risk of exposure of the
unvaccinated group compared to the vaccinated group,”
quantifies the discrepancy in exposure to the virus of the
vaccinated and unvaccinated population.
The main result of the paper is presented in Section 3
and consists in quantifying the relation between effectiveness, efficacy and degree of discrimination. We also discuss its possible consequences.
In Section 4 we perform similar considerations regarding the vaccine effectiveness regarding hospitalization,
while in Section 5 we illustrate the theoretical results by
examples related to the COVID-19 pandemy in Germany
and the UK. We consider statistical data from November 2021, before the emergence of the omicron variant of
SARS-CoV-2.
www.sporajournal.org
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Efficacy and Degree
of Discrimination

We next define the terms which are used in this paper.
Definition 1. The vaccine efficacy V E ∗ is defined as
V E∗ = 1 −

PE (I | V )
.
PE (I | V ′ )

(6)

We point out that this definition is consistent with
the standard usage of the term “efficacy” in epidemiology. Indeed, this notion is associated with clinical trials
based on appropriate designs, where the assumption of
independence of exposure and vaccination status can be
made. If we assume that the trials are performed before a massive vaccination campaign of the population
is started, then usually one compares two equally sized
groups which are also statistically homogeneous, meaning
that P (V ) = P (V ′ ) = 0.5 and P (V ∩E) = P (V ′ ∩E), that
is, the number of exposed individuals in each group should
be in principle the same. In fact, this implies the independence of V and E: Since P (E) = P (V ∩ E) + P (V ′ ∩ E),
this means that P (V ∩ E) = P (V ′ ∩ E) = 0.5 · P (E) =
P (V ) · P (E) = P (V ′ ) · P (E).
We finally note that the conditional probabilities involved in computing the efficacy from Definition 1 rely
on information on exposure, which in practice is difficult
to collect. An instrument for estimating them is a stratified analysis according to variables that may correlate
with exposure to infection [4].
Definition 2. The degree of discrimination D is defined
as
P (E | V ′ )
.
(7)
D =1−
P (E | V )
This term is a measure for the discrepancy in exposure
to the virus between vaccinated and unvaccinated individuals. In the COVID-19 context, the additional restrictions imposed only on the latter, together with their more
risk-averse behaviour, lead to a decrease the exposure
probability P (E | V ′ ) compared to the value P (E | V )
for the vaccinated population. Therefore in this paper
we make the assumption D ≥ 0. The maximal value is
D = 1, which is attained if unvaccinated individuals are
not exposed to the virus at all, meaning the complete
isolation of them.

3

The Relation Between
Effectiveness, Efficacy, and
Degree of Discrimination

In this section we state the main result of this paper and
discuss possible consequences.
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Theorem 1. Between the quantities V E, V E ∗ , and D
the relation
1 − V E ∗ = (1 − V E) · (1 − D)

where in the last step formula (3) was used.
Taking into account Definitions 1 and 2, this is equivalent to 1 − V E ∗ = (1 − V E) · (1 − D), which is exactly
(8)
the statement of the theorem.

holds.
Proof. Conditioning by the event E, the exposure to the
virus during a given time interval, we compute the relative
risk as
PE (V ∩ I)
PE (V ′ )
PE (I | V )
=
·
PE (I | V ′ )
PE (V )
PE (V ′ ∩ I)
P (V ∩ I ∩ E)
P (E)
PE (V ′ )
=
·
·
P (E)
P (V ′ ∩ I ∩ E) PE (V )
PE (V ′ )
I⊆E P (V ∩ I)
=
·
(9)
P (V ′ ∩ I) PE (V )
P (V | I)P (I) PE (V ′ )
·
=
P (V ′ | I)P (I) PE (V )
P (V | I) PE (V ′ )
=
·
.
(10)
P (V ′ | I) PE (V )

In the following we will discuss some consequences of
this result.
In the present paper, under the assumption D ≥ 0,
from (8) can be easily seen that V E ∗ ≥ V E, that is, the
efficacy is always larger than the observed effectiveness.
Moreover, the result of Theorem 1 can be also stated
as
1 − V E∗
.
(11)
VE =1−
1−D
The above formula implies that for D ≥ V E ∗ we have
V E ≤ 0, i.e. a negative observed effectiveness if the degree of discrimination is larger than the efficacy. This may
happen especially if we consider the efficacy regarding all
types of infection, not only symptomatic. In this case
its value is much lower than regarding only symptomatic
infections and the degree of discrimination is likely to
surpass it. This gives a mathematical explanation for the
negative observed effectiveness in the UK [6, p. 33] since
its value is computed regarding all kind of infections, not
only symptomatic. But this does not mean at all that the
vaccines do not protect. The probability of infection of
the vaccinated individuals is in fact higher due to their
higher exposure, implied by a higher degree of discrimination, but the efficacy of the vaccines is always larger
than the observed effectiveness.

Before going on with the computation, we point out the
correspondence to the concepts from [4], where the vaccinated and unvaccinated status are denoted by 1 and
0, respectively. Probabilities conditioned on exposure to
the virus are called transmission probabilities. The conditional probability PE (I | V ) is the transmission probability p·1 to the vaccinated susceptibles conditioned by
exposure due to contact to infected individuals of any
vaccinated status. The dot means that the infective contact may have any status 0 or 1, otherwise transmission
probabilities can be also differentiated according to the
Real Effectiveness
vaccination status. Similarly we have that PE (I | V ′ ) is 4
the transmission probability p·0 to the unvaccinated susRegarding Hospitalization
ceptibles.
Moreover, from (9) we obtain
In contrast to the values of the observed effectiveness
regarding the protection against all infections (not only
P (V ∩ I) PE (V ′ )
P (V ∩ I) P (V ′ ∩ E)
P (E)
·
=
·
·
′
′
P (V ∩ I) PE (V )
P (V ∩ I)
P (E)
P (V ∩ E) symptomatic), which can be relatively low, the data related to the protection of the COVID-19 vaccines against
′
P (V ∩ I) P (V ∩ I)
severe cases, which may lead to hospitalization, treatment
=
/
P (V ∩ E) P (V ′ ∩ E)
in intensive care or death still show high values. In this
SAR·1
section we will discuss and explain this fact within the
=
SAR·0
framework introduced previously, considering exemplarthat is, the relative risk computed here equals to the ra- ily the event of hospitalization, denoted with H.
tio of the secondary attack rates of the vaccinated and
Definition 3. a) We define the observed effectiveness
unvaccinated susceptibles respectively.
regarding hospitalization V EH similarly to (1) or (3):
By Bayes’ formula we obtain the following from (10):
P (H | V )
P (V | H) P (V ′ )
P (V |I) P (E|V ′ ) · P (V ′ )
P (E)
PE (I | V )
V EH = 1 −
=1−
·
. (12)
′
=
·
·
P (H | V )
P (V ′ | H) P (V )
P (I | V ′ )
P (V ′ |I)
P (E)
P (E|V ) · P (V )
E

P (V | I) P (V ′ ) P (E | V ′ )
·
·
P (V ′ | I) P (V ) P (E | V )
P (E | V ′ )
= (1 − V E) ·
,
P (E | V )
=
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b) Similarly to (6) and (10) we define the real effectiveness regarding hospitalization:
∗
V EH
= 1−

PI (H | V )
P (V | H) P (V ′ | I)
= 1−
·
. (13)
′
PI (H | V )
P (V ′ | H) P (V | I)
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For the real effectiveness regarding hospitalization it
is therefore meaningful to take conditional probabilities
with respect to I that is, we use the relative risk of hospitalization of vaccinated versus unvaccinated given that
an individual is (symptomatically) infected.
The main result in this context is then the following.
∗
Theorem 2. Between the quantities V EH , V EH
and V E
the relation
∗
1 − V EH = (1 − V E) · (1 − V EH
)

(14)

holds.
Proof. Using successively Bayes’ formula, (12) and (1) we
obtain
P (V | H) P (V ′ ) P (I | V ′ )
·
·
P (V ′ | H) P (V ) P (I | V )
P (I | V ′ )
= 1 − (1 − V EH ) ·
P (I | V )
1 − V EH
,
=1−
1−VE

∗
V EH
=1−

(15)

and from this the result of the theorem readily follows.
We can therefore compute the real effectiveness regarding hospitalization in terms of the observed effectiveness
regarding hospitalization and infection. From Theorem 2
follows
1 − V EH
∗
1 − V EH
=
,
(16)
1−VE
a formula which has several consequences. We note
that if V E = 0, the two measures for effectiveness regarding hospitalization coincide. A simple computation shows
∗
, while for V E < 0 we
that V E > 0 implies V EH > V EH
∗
. We note that in the normal situation
have V EH < V EH
of a positive observed effectiveness against symptomatic
infections, the real effectiveness regarding hospitalization
is smaller than the observed one, in contrast to the relationship between the effectiveness regarding symptomatic
infection and the efficacy, which in real life is the other
way around. However, in the regime of negative observed
effectiveness, typically related to all types of infection, the
real effectiveness regarding hospitalization is larger than
the observed one.

5

Numerical Examples
Based on COVID-19 Data

The data from Germany [5], p. 25 and p. 19 respectively,
show that in summer 2021, in week 30, the observed effectiveness against symptomatic infections in the age group
18–59 was around V E = 0.8 at a vaccination rate of
www.sporajournal.org
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P (V ) = 0.5, while in November same year, in week 46, the
two factors were about V E = 0.68 and P (V ) = 0.75. Assuming a generic plausible value of V E ∗ = 0.9 [6, p. 10],
this would imply the values for the degree of discrimination of D = 0.5 and D = 0.69 in weeks 30 and 46,
respectively. This is consistent with the observation that
starting with end of August 2021 the so-called 3G-rule
was introduced (geimpft-genesen-getestet) which allows
access to several public places only with a “green pass”
showing the status of vaccinated, recovered or negatively
tested. Moreover, since October 11, the fast antigen tests
weren’t for free anymore, while starting with Week 46, 3G
was replaced with 2G, allowing access only to vaccinated
or recovered individuals. The effect of these measures is
obviously an increase of the degree of discrimination D.
According to the UKHSA [6, p. 33] in weeks 43–46 of
2021, within the age group 40–59 the incidence rates
(regarding symptomatic and asymptomatic infections)
among the vaccinated individuals were about twice as
large as in the case of unvaccinated, implying an observed
effectiveness of V E = −1. Assuming a degree of discrimination of D = 0.7 similar to Germany, this would yield
an efficacy of V E ∗ = 0.4 against any infections (not only
symptomatic), which is a plausible value. At a degree
of discrimination D = 0.5 we would have V E ∗ = 0, i.e.
an efficacy of 0 against any infections. But such a small
value of D, similar to the value in Germany in summer
2021, where the cases and also the restrictions were at a
low level, is rather unrealistic.
We will consider next the effectiveness against hospital∗
accordization and compute the real effectiveness V EH
ing to (15). In Germany, in week 30 of 2021, for the age
group 18–59 we have an observed effectiveness V EH = 0.9
∗
at V E = 0.8, so we obtain V EH
= 0.5. In week 46, for
∗
= 0.375.
V EH = 0.8 and V E = 0.68 we obtain V EH
Note that the real effectiveness against hospitalization is
computed here conditioning on symptomatic infection.
If we compute this quantity by conditioning on any
infection, assuming V E ∗ = 0.4 and D = 0.7 implies as
above the value V E = −1. Assuming for example V EH =
∗
0.8 for week 46 in Germany we obtain V EH
= 0.9. In
week 30 we computed D = 0.5 and with the assumed
value of V E ∗ = 0.4, we obtain for the observed effectiveness conditioned by all infections V E = −0.2. Assuming
∗
V EH = 0.9, we obtain V EH
= 0.916.
In the UK, in weeks 43–46, in the age group 40–59
the rates of hospitalization for unvaccinated were about
four times larger than for vaccinated, implying V EH =
0.75. As we previously noted, here we have V E = −1
∗
considering all infections, which implies V EH
= 0.875.
The conclusion of this analysis is that the COVID-19vaccines yield a high real effectiveness of about 90% regarding hospitalization if we condition on any infection,
while at conditioning only on symptomatic infections, the
2022 Volume 8(1) page 59
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real effectiveness is significantly reduced, at about 40–
50% from this value. The interpretation of this fact is
that vaccinated individuals develop in most cases only
asymptomatic infections, which reduces the hospitalization rate if we condition on all types of infections.
As an additional remark we note that the UK and
Germany use different testing strategies. According to
the website https://ourworldindata.org/explorers/
coronavirus-data-explorer, in November 2021 in Germany were performed per 1000 people between 2–3 tests,
while in the UK the number is much higher, of about
12–14 tests per 1000 people, so by a factor of 5–6 larger.
The main explanation is that the regulations in Germany
imply that vaccinated individuals have a reason for testing only if they are symptomatic. Either voluntarily,
if one suspects a COVID-19 infection, or compulsory, if
the person had contact to a known case and additionally
manifests symptoms. Therefore, the asymptomatic infections, especially under the vaccinated, are much underestimated. This explains the fact that in official German
statistics the effectiveness of vaccines is evaluated only regarding symptomatic infections. In the UK however, due
to the significantly higher test frequency, the estimation
of the asymptomatic infections is much better and can be
used in the statistics.

Guiaş

of about 37–50%.
We conclude that the COVID-19 vaccines show in general a high efficacy regarding symptomatic infections and
a low efficacy regarding any infections. Vaccinated individuals develop therefore mostly asymptomatic infections, a case in which there is no reason for hospitalization, meaning a high effectiveness regarding hospitalization if conditioning on any infections. However, if conditioned on symptomatic infections, the effectiveness regarding hospitalization is significantly lower.

References
[1] Baum, U., Kulathinal, S., and Auranen, K. (2021).
Exposure Misclassification Bias in the Estimation of
Vaccine Effectiveness. PLoS ONE, 16(5):e0251622.
doi:10.1371/journal.pone.0251622
[2] Farrington, C. P. (1993). Estimation of Vaccine Effectiveness Using the Screening Method. International
Journal of Epidemiology, 22:742–746.
[3] Fedson, D. S. (1998). Measuring Protection: Efficacy Versus Effectiveness. Developments in Biological
Standardization, 95:195–201.

[4] Halloran, M. E., Struchiner, C. J., and Longini,
I. M., Jr. (1997). Study designs for evaluating dif6 Summary
ferent efficacy and effectiveness aspects of vaccines.
American Journal of Epidemiology, 146(10):789–803.
In this paper we propose a Bayesian approach linking
doi:10.1093/oxfordjournals.aje.a009196
effectiveness and efficacy of vaccines with the so called
degree of discrimination, a factor which quantifies the [5] Robert Koch Institut (2021). Wöchentlicher
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